To the Editor: With their elegant study of sertraline and desmethylsertraline levels in maternal breast milk and the serum of nursing infants, Zachary N. Stowe, M.D., and colleagues have made a major contribution to the debate over the use of psychotropic medications during lactation R7115511CHDCHIGF. However, although this and several smaller studies have demonstrated minuscule or unmeasurable levels of various antidepressants in breast-fed infants, there remain understandable concerns about prescribing such medications to lactating mothers. Given the important role of serotonin in the modulation of synaptogenesis in the neonatal period R7115511CHDDCCJC, such concerns might apply particularly to the use of selective serotonin reuptake inhibitors (SSRIs).

Most studies have concentrated on measuring the serum levels of antidepressants in infants, rather than their effects. A recent study, however, found no discernible effect of maternal sertraline treatment on the activity of the platelet serotonin transporter in four breast-fed infants R7115511CHDDAGEB. These represent the first data on the potential biological effects of maternal antidepressant treatment on infants.

The benefits of breast-feeding need no repeating R7115511CHDCHGCH, but an issue often overlooked is the risk to the infant associated with unresolved maternal depression. Children of mothers with untreated postpartum depression have reduced growth rates, delayed motor development, and lower IQs than children of mothers whose depression has been successfully treated R7115511CHDCIIHJR7115511CHDBFBFE. In addition, we must consider the potentially devastating effects upon a child of maternal psychiatric hospitalization or suicide.

It is clear that more data are needed, particularly from longitudinal developmental studies, before we can be sure that infant exposure to SSRIs through breast milk is harmless. Nonetheless, given the enormous benefits associated with breast-feeding, the significant risks posed by untreated maternal depression, the mounting evidence that SSRIs are not found in significant quantities in infant plasma, and early data suggesting they do not produce measurable changes in infant serotonin transport, we feel that all women suffering from significant postpartum depression should be offered appropriate antidepressant treatment unless there is a clear contraindication in an individual case.